Hepatobiliary tract cancers (HBTCs) are a heterogeneous group of cancers with high mortality. Because most of these cancers, with the exception of hepatocellular carcinoma (HCC), are rare, few data are available concerning the population level survival expectations of patients with HBTC. Here, we describe survival of patients with HBTC in Germany with comparison to survival in the US. Therefore, data were extracted from 12 databases in Germany and the Surveillance, Epidemiology and End Results (SEER13) database in the US. Period analysis and modeled period analysis were used to calculate 5-year relative survival estimates for patients with HBTC diagnosed from 1997 to 2013. HCC was the most common HBTC in each database, accounting for over 1/3 of HBTC in Germany and about half of cases in the US. Overall age adjusted 5-year relative survival for HBTC in 2006-2013 was 19.1% in Germany and 20.6% in the US. Five-year relative survival increased by 3.8% units in Germany and 4.5% units in the US between 2002-2005 and 2010-2013. Five-year relative survival for individual types of HBTC ranged from 9.8% in Germany and 2.9% in the US for not otherwise specified biliary tract cancers to 44.4% and 50.1%, respectively, in Germany and the US for duodenal cancers. In conclusion, survival for HBTC remains poor in both Germany and the US, although a small increase in survival in the past decade was observed. Further work to find better treatment options for HBTC is needed to improve survival.
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Background
Hepatobiliary tract cancers (HBTCs) are a heterogeneous group of cancers affecting the liver and biliary tract. Worldwide, HBTCs are the second leading cause of cancer death among men, but the fifth most common cause of cancer mortality in developed countries. 1, 2 The cancer mortality for HBTC is high relative to the incidence, that is, they make up the 10th most common cancer in men by incidence but the 6th by mortality in the US. 2 A majority of these cancers (70-90%) are hepatocellular carcinomas (HCCs). HCC is much more common in less developed countries, particularly those with high rates of chronic hepatitis B infection and higher risk of aflatoxin contaminated food. In contrast, primary biliary tract cancers are only slightly more common in less developed countries compared to developed countries. 1 HCC rates are increasing in countries with historically low rates of HCC, although they are falling in countries with historically high rates. A number of factors, including increased use of hepatitis B vaccination, especially in hepatitis B endemic areas, increases in obesity, and increased risk of hepatitis C infection in some developed countries may account for this mixed picture. 1,2 HBTC are clinically heterogeneous but tend to be chemotherapy resistant and have poor 5-year survival expectations.
In the past, it has been difficult to examine survival for rare cancers in Germany due to lack of high quality population level data from a unified database. In 2008, a collaborative project was set up between population-based German cancer registries and the German Cancer Research Center to provide comprehensive data on cancer survival in Germany. 3 This collaboration allows for the study of relatively rare cancers, such as the non-HCC HBTC as well as more in-depth examination of survival in more common cancers such as HCC.
Here, we examine survival for patients diagnosed with HBTC in Germany and the US by age and specific tumor type.
Methods

Data sources
A detailed description of the German cancer registries from which data were obtained has been published previously. 3, 4 Briefly, data extracted from 12 cancer registries throughout Germany, representing a total base population of 28 million people, were initially extracted.
Patients age 15 years or older with a primary diagnosis of any HBTC, including HCC, intrahepatic cholangiocarcinoma (ICC), extrahepatic cholangiocarcinoma (ECC), gall bladder cancer (GBC), ampulla of Vater cancer (AOV), biliary tract not otherwise specified (NOS/BT) and overlapping biliary tract cancers (OverlpBT) (detailed ICD-10 codes in Table 1) in 1997-2013 and with mortality follow-up through December 2013, with or without preceding cancers, were included (Table 1) . Due to the topographical nearness, duodenal cancers were also included. For some registries, data were available starting from later years only. Cases that were recorded by death certificate only (DCO) were excluded.
To compare population level survival for HBTC in Germany with survival in the US, data from the Surveillance, Epidemiology and End Results (SEER13) database were analyzed. 5 The same inclusion criteria as for patients from the German cancer registries were applied for the same time period. The SEER13 database includes data from 13 regional cancer centers in the US, covering a population of about 41.5 million people. Centers are chosen for inclusion based on their high quality and epidemiologically interesting population groups. The SEER population is considered to be similar to the general US population with respect to most sociodemographic characteristics, although it may be more affluent than average and may have slightly higher than average survival for some cancers. 6 
Statistical methods
One-and five-year relative survival estimates for the time period 2006-2013 were calculated using period analysis. 7 Period analysis, first introduced in 1996, 8 provides more upto-date survival estimates than traditional cohort based analysis. In particular, it has been shown by extensive empirical evaluation, that period estimates of 5-year relative survival for a given period quite closely predict 5-year relative survival later observed for patients during the period of interest. 9, 10 To make survival estimates comparable between both countries, age-adjusted survival estimates were derived by computing weighted sums of age-specific survival estimates using weights according to the international cancer survival standard (ICSS) weight adapted for 5 age groups (15-44, 45-54, 55-64, 65-74 and 751 years). 11 Because survival in HBTC varies with age and sex, we examined survival by major age groups and by sex. Differences in survival between patients in Germany and the US were tested for statistical significance, overall and by single age groups, using modelbased period analysis. 12 In model-based analysis, numbers of deaths were modeled as a function of period of follow-up, age group, and country by Poisson regression with the logarithm of the person-months at risk as offset. HBTC are a heterogeneous group of cancers. Therefore, age-adjusted relative survival and, where possible, age specific survival estimates were calculated for individual HBTC types. Trends in survival were examined, comparing 5-year survival for the period 2002-2005, 2006-2009 to 2010-13 to determine whether the prognosis of patients with HBTC was changing over time overall or for any specific age groups. In addition, survival trends were calculated for HCC, the most common form of HBTC, all non-HCC HBTC together, and other individual forms, where possible. To investigate whether there might be trends in surgical resection rates that could explain changes in relative survival, stratified trend analyses by surgical resection received (yes vs. no) were performed for the US for which highly complete data on surgery What's new? Cancers of the hepatobiliary tract (HBTC) carry poor survival expectations but little is known about survival rates in patients with different histological subtypes. Here the authors compared the survival of individuals afflicted with HBTC in Germany and the US controlling for histology and age at diagnosis. They find a small increase in survival in the past decade although survival overall remains poor in both countries. They attribute the small increase in survival to earlier diagnosis rather than better treatment as resection rates remained largely unchanged.
were available (for 95.7% of patients compared to 16.3% for patients in Germany).
Relative survival was calculated as the ratio of actual (observed) survival to expected survival. Expected survival was estimated according to the Ederer II method 13 using national life tables stratified by age, sex and calendar year obtained from the German Federal Statistical Office.
14 Relative survival for the US patients was calculated using US sex, age, calendar year and race specific life tables published by the Center for Disease Control (CDC). 15 All calculations were carried out using SAS software (version 9.2), using macros developed for standard and modeled period analysis. 12, 16 A p values below 5% in two-sided testing was considered as significant. The analysis with SAS was carried out by two independent analysts to ensure quality of the results.
Results
Overall, after exclusion of DCO cases, 55,163 cases of HBTC were identified in the German database between 1997 and 2013 for inclusion in the study. The median age at diagnosis was 71 years overall, with median ages ranging from 69 years for HCC and ICC to 74 years for GBC (Table 1) . HCC was the most common cancer type with 20,240 cases. In comparison, 67,939 cases were identified in the US database after exclusion of DCO cases. The median age was lower in the US at 67 years, with ages ranging from 63 years for HCC to 73 years for ECC, OverlpBT and NOS/BT. HCC was also the most common cancer at 38,349 cases and in comparison with Germany had a higher proportion of all HBTC cases (36.9% vs. 56.6%). Overall DCO proportions were 21.0% in Germany and 1.7% in the US.
Generally, resection rates in the US fluctuated minimally and depended on each cancer entity when analyzed by year of diagnosis, but no clear trend could be found (e.g., for all cancer entities 30.3% in 1997-2001 to 30.6% in 2010-2013; Supporting Information Table S1 ). When resection rates were investigated by analyzed periods, also the graphical illustration did not indicate any meaningful changes in resection rates (Supporting Information Fig. 1 ).
One-year relative survival was calculated for HBTC to examine short term survival for these cancers. Overall age adjusted 1-year relative survival was 46.7% in Germany and 48.1% in the US (Table 2) . Because HBTC are a heterogeneous group of cancers and survival may vary between different subtypes, we examined 1-and 5-year survival for individual cancer sites. Survival varies by location, with 1-year survival ranging from 22.1% for NOS/BT in the US to 70.4% for AoV in Germany and 5-year survival estimates varying from 2.9% for NOS/BT in the US to 50.1% for duodenal cancer in the US. One-year and 5-year survival estimates were higher for Germany for ECC, NOS/BT and ICC and higher in the US for HCC and GB. For duodenal cancer, only 5-year survival was significantly higher in the US. No significant differences were observed for other cancers.
Overall age adjusted 5-year survival for patients with HBTC in Germany in 2006-2013 was 19.1% (Table 2) . Survival varied with age, with 5-year relative survival estimates ranging from 33.3% for ages 15-44 years to 13.4% for age 751 years (Table 3) . Five-year age-adjusted relative survival was 20.6% overall for the US (Table 2) , with point estimates of survival from 32.6% for age 15-44 years to 13.2% for ages 751 years. Differences in survival estimates between the two countries ranged from 23.5% for ages 65-69 years to 10.9% for ages 45-54 years and were significantly higher in the US overall and for ages 55-74 years.
Age-group specific survival was calculated for those cancers for which case numbers were sufficient. Five-year relative survival for HCC in Germany was 17.8% overall, ranging from 35.3% for age 15-44 years to 12.2% for age 751 years (Tables 2 and 3 ). Survival estimates for the US were slightly higher, at 19.0% overall, ranging from 29.1% for 15-44 years to 11.4% for 751 years. Five-year survival was considerably lower for ICC, with overall survival estimates of 10.6% and 8.4%, respectively, in Germany and the US. Survival estimates for ECC were slightly higher for ICC, although lower for Trend analysis was performed age-specifically for patients with HCC and a composite group of non-HCC HBTC. A small increase in overall age adjusted 5-year survival was observed for HCC in both Germany and the US, with survival increasing from 14.2% to 18.7% in Germany and 14.2% to 19.9% in the US (Table 4) . Statistically significant increases in survival were observed for patients of all age groups in both Germany and the US, except the youngest age group between 15 and 44 years in Germany.
Similarly, there was a small increase in survival for patients with non-HCC HBTC, with age adjusted 5-year relative survival increasing from 17.3% to 20.7% in (Table 5) . Case numbers were too small to allow age specific analysis of specific sites besides HCC, but age adjusted survival for ICC, ECC, GB, duodenal cancer and NOS/BT showed small increases in survival for each of these cancer sites, except for ICC in the US, duodenal cancer in Germany and NOS/BT for both countries. Duodenal cancer changed from 2002-2005 to 2010-2013 in the US significantly with 12.0% units. The only other significant increases were found for ICC, ECC and GB in Germany.
Stratified by surgical resection, those patients who have received surgery showed a much higher relative survival than those who did not (Supporting Information Tables S2 and  S3 , respectively). However, for almost all cancer entities, a significant trend toward increased relative survival could be found, both in patients who underwent surgical resection and those who did not (e.g., for all entities 37. 
Discussion
Survival for HBTC is low in both Germany and the US. Survival was slightly lower in Germany than the US overall, although the absolute differences were small and age adjusted relative survival was higher in Germany for ICC, ECC, AoV and NOS, whereas it was higher in the US for HCC, Duodenal and GB cancer. Survival estimates were higher in 2010-2013 compared to 2002-2005, but again the absolute differences between these two time periods was small. Survival varied with subtype of HBTC, with the highest estimates being observed for AoV and duodenal cancer, the lowest for NOS 
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Pulte et al. and overlap. Increases in survival were observed for both HCC and some non-HCC subtypes, but absolute increases were small for both groups. To our knowledge, this is the first population level examination of survival in HBTC in Germany. Prior studies of HBTC in the US are also sparse and few or no studies examine survival for individual types of HBTC, with the exception of HCC. One study examining survival for cholangiocarcinomas between 1973 and 2002 demonstrated a slow increase in survival over that time period, with most of the increase being accounted for by increased survival in patients with resectable tumors. 17 A recent study examining HCC incidence and mortality in the US suggested that both are decreasing, but survival was not examined in this study. 18 Our data demonstrate low 5-year survival for patients with HBTC in both Germany and the US, with slightly lower survival in Germany overall and for HCC, although mixed results for other HBTC. A higher percentage of patients in the US were diagnosed with HCC, which may account for some of the difference in overall survival. 
Pulte et al.
The hepatobiliary cancers are rare cancers, with the exception of HCC, and treatment options for HBTC are very limited. Surgery is the treatment of choice for potentially resectable HBTC and is the only potentially curative therapy currently available. [19] [20] [21] Traditional chemotherapeutic agents produce only rare responses in non-HCC HBTC 20 and have almost no effect on HCC, 21 but several novel therapies, including embolization and targeted therapies, have been demonstrated to be effective in later stage HCC, although long-term survival is rare. 22, 23 Recently, studies of PD-1 inhibitors have shown promise in HCC, 24 but the results are preliminary and the role of immunotherapy including PD-1 inhibitors in HCC and other HTBC is not yet defined. Occasionally, HCC that is too advanced to cure with resection or in the setting of cirrhosis can be cured with liver transplantation. 23 The outlook for other HBTC in advanced stages continues to be poor.
Our data indicate that 5-year survival has increased marginally for HBTC in the past decade, both for HCC and other types. This increase is more likely related to earlier diagnosis, possibly increased incidental diagnoses, than to changes in therapy, although, as noted earlier, changes in HCC therapy may have led to some increase in survival. In addition, changes in the etiology of HCC, that is, a decrease in the number of cases related to hepatitis B versus other etiologies (hepatitis C, non-alcoholic steatohepatitis and others) may have changed the natural history of HCC to some extent.
Moreover, the results stratified by surgical resection do not support the hypothesis that changes in surgical resection may have contributed to an increase in relative survival among HBTC patients, since resection rates essentially remained stable over time and an increase was also apparent in non-resected patients for most of the cancer entities. Strengths of our study include the use of large population based databases to determine survival for each country, allowing for detailed examination of survival by age group for these rare tumors and some examination of specific tumor types within the general category of HBTC. The availability of data for more than a decade in each database allows for examination of population-based survival and changes in population based survival over time in each country. Prior studies have demonstrated that population level survival is different from survival observed in clinical trials. 25 Thus, use of population level data is important to determine the actual survival expectations of patients in the "real world" environment, as opposed to the patients in clinical trials who are often younger and have fewer comorbid conditions than the average patient. Finally, the use of period analysis and modeled period analysis provide the most up-to-date possible survival estimates, allowing for a more realistic picture of current survival as compared to traditional cohort analysis.
Some limitations should be considered in interpreting the results. First, despite the use of the large population database, the rarity of HBTC limits our ability to detect small differences in survival. Second, HBTC are a heterogeneous group of conditions and detailed examination of survival is not possible for some of the less common subtypes. Third, the absence of a national death index in Germany means that cancer registries rely on record linkage with vital statistics from the region that they cover and may miss deaths among patients who leave the region. However, previous studies suggest that the potential overestimation of survival due to migration is very small. 4 In addition, no analysis by stage was performed both due to the relatively rarity of the tumors and because the stage was missing for a large proportion of the cases in the German database. In addition, analyses by surgical resection were only meaningful for the US data, given limited completeness of the German data on treatment.
Finally, the higher proportion of DCO notifications in Germany might affect survival estimates. We addressed this concern by calculating a plausibility range for data from the German databases. The plausibility range is the range in which actual survival is expected to fall after accounting for DCO cases under plausible assumptions. 26, 27 The plausibility range for overall 5-year age adjusted relative survival in Germany was 16.8% to 19.1%, a range of 2.3% units. Thus, it is unlikely that the differences in DCO rate have led to a major overestimation of survival. In summary, our results demonstrate that survival is low for patients with HBTC in both Germany and the US. Survival is slightly higher in the US, with clear differences of a few percentage units for HCC and less consistent differences for other HTBC. A small increase in survival between 2002-2005 and 2010-2013 was observed for both countries, with increases being observed for both HCC and non-HCC. However, population level 5-year survival remains low in both countries, demonstrating a continued need for further investigation of potential treatments for HBTC.
